These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Current perspective of HCV NS5B inhibitors: a review. Patil VM; Gupta SP; Samanta S; Masand N Curr Med Chem; 2011; 18(36):5564-97. PubMed ID: 22172066 [TBL] [Abstract][Full Text] [Related]
25. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors. Yu H; Fang Y; Lu X; Liu Y; Zhang H Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500 [TBL] [Abstract][Full Text] [Related]
26. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Ryu K; Kim ND; Choi SI; Han CK; Yoon JH; No KT; Kim KH; Seong BL Bioorg Med Chem; 2009 Apr; 17(8):2975-82. PubMed ID: 19332375 [TBL] [Abstract][Full Text] [Related]
27. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. Koch U; Narjes F Infect Disord Drug Targets; 2006 Mar; 6(1):31-41. PubMed ID: 16787302 [TBL] [Abstract][Full Text] [Related]
28. The conserved lysine 151 of HCV NS5B modulates viral genome replication and infectious virus production. Haqshenas G J Viral Hepat; 2012 Dec; 19(12):862-6. PubMed ID: 23121364 [TBL] [Abstract][Full Text] [Related]
29. Enzymatic characterization of the full-length and C-terminally truncated hepatitis C virus RNA polymerases: function of the last 21 amino acids of the C terminus in template binding and RNA synthesis. Vo NV; Tuler JR; Lai MM Biochemistry; 2004 Aug; 43(32):10579-91. PubMed ID: 15301555 [TBL] [Abstract][Full Text] [Related]
30. Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors. Zhao C; Wang Y; Ma S Eur J Med Chem; 2015 Sep; 102():188-214. PubMed ID: 26276434 [TBL] [Abstract][Full Text] [Related]
31. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors. Musmuca I; Caroli A; Mai A; Kaushik-Basu N; Arora P; Ragno R J Chem Inf Model; 2010 Apr; 50(4):662-76. PubMed ID: 20225870 [TBL] [Abstract][Full Text] [Related]
32. Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase. Harikishore A; Li E; Lee JJ; Cho NJ; Yoon HS Mol Divers; 2015 Aug; 19(3):529-39. PubMed ID: 25862642 [TBL] [Abstract][Full Text] [Related]
33. Update on different aspects of HCV variability: focus on NS5B polymerase. Marascio N; Torti C; Liberto M; Focà A BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S1. PubMed ID: 25234810 [TBL] [Abstract][Full Text] [Related]
34. Specific interaction between the hepatitis C virus NS5B RNA polymerase and the 3' end of the viral RNA. Cheng JC; Chang MF; Chang SC J Virol; 1999 Aug; 73(8):7044-9. PubMed ID: 10400807 [TBL] [Abstract][Full Text] [Related]
35. Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase. Amin A; Zaccardi J; Mullen S; Olland S; Orlowski M; Feld B; Labonte P; Mak P Virology; 2003 Aug; 313(1):158-69. PubMed ID: 12951030 [TBL] [Abstract][Full Text] [Related]
36. Expression of hepatitis C virus NS5B protein: characterization of its RNA polymerase activity and RNA binding. Ishii K; Tanaka Y; Yap CC; Aizaki H; Matsuura Y; Miyamura T Hepatology; 1999 Apr; 29(4):1227-35. PubMed ID: 10094969 [TBL] [Abstract][Full Text] [Related]
37. Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. Shimakami T; Hijikata M; Luo H; Ma YY; Kaneko S; Shimotohno K; Murakami S J Virol; 2004 Mar; 78(6):2738-48. PubMed ID: 14990694 [TBL] [Abstract][Full Text] [Related]
38. An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors. Caillet-Saguy C; Simister PC; Bressanelli S J Mol Biol; 2011 Dec; 414(3):370-84. PubMed ID: 22008450 [TBL] [Abstract][Full Text] [Related]
39. Nonstructural protein 5A (NS5A) and human replication protein A increase the processivity of hepatitis C virus NS5B polymerase activity in vitro. Mani N; Yuzhakov A; Yuzhakov O; Coll JT; Black J; Saxena K; Fulghum JR; Lippke JA; Rao BG; Rijnbrand R; Kwong AD J Virol; 2015 Jan; 89(1):165-80. PubMed ID: 25320291 [TBL] [Abstract][Full Text] [Related]
40. Quinolones as HCV NS5B polymerase inhibitors. Kumar DV; Rai R; Brameld KA; Somoza JR; Rajagopalan R; Janc JW; Xia YM; Ton TL; Shaghafi MB; Hu H; Lehoux I; To N; Young WB; Green MJ Bioorg Med Chem Lett; 2011 Jan; 21(1):82-7. PubMed ID: 21145235 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]